. Author manuscript; available in PMC: 2013 Sep 16.

Published in final edited form as: Aliment Pharmacol Ther. 2010 Sep 3;32(9):1174–1183. doi: 10.1111/j.1365-2036.2010.04449.x

Table 1.

Select clinical characteristics of cases with liver injury after exposure to duloxetine

Clinical Characteristics	Total (N=7)
Demographics:
Median Age (25^th, 75^th) Years	49 (43, 54)
Female gender	6 (86%)
Self-reported Race
White or Caucasian	6 (86%)
Black or African American	1 (14%)
Median BMI (25^th, 75^th) (kg/m2)	32.3 (28.4, 33.1)
Pre-Existing Medical Conditions:
Underlying liver disease	2
Prior Drug Allergies	3 (43%)
Alcohol Use	1 (14%)
Diabetes/endocrine disorder	1 (14%)
Neurological disease	3 (43%)
Congestive heart failure	0
Chronic renal disease	0
Dosage, mg/day
60	5 (71%)
30	2 (29%)
Median Duration of exposure (25^th,75^th), days	46 (32, 57)
Latency period, Median (25^th,75^th), days
Onset of symptoms	50 (34,59)
Onset of lab abnormalities	50 (35,56)
Onset of jaundice	50 (40,57)
Reported symptoms profile
Itching	3 (43%)
Nausea	6 (86%)
Pain	5 (71%)
Rash	1 (14%)
Fever	3 (43%)
Median absolute eosinophils per mm³(25^th,75^th)	128 (120–354)
Positive auto-antibodies	3 (43%)
Other organ dysfunction
Acute renal dysfunction	2 (29%)
Altered mental status	1 (14%)
Thrombocytopenia	1 (14%)